CELLECTIS - ADR (CLLS) Stock News

USA - Nasdaq - NASDAQ:CLLS - US15117K1034 - ADR

5.22 USD

+0.09 (+1.75%)

Last: 12/11/2025, 8:27:22 PM

5.22 USD

0 (0%)

After Hours: 12/11/2025, 8:27:22 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CLLS Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Cellectis Inc.

ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire

4 days ago - By: Cellectis Inc.

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

4 days ago - By: Cellectis Inc.

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

8 days ago - By: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

22 days ago - By: Benzinga

Why Cellectis Stock Is Trading Higher Today

a month ago - By: Benzinga

Cellectis Earnings Preview

8 days ago - By: Cellectis Inc.

Monthly information on share capital and company voting rights

15 days ago - By: Cellectis Inc.

Cellectis organise un webinaire dédié aux actionnaires français le jeudi 4 décembre 2025

23 days ago - By: Cellectis Inc.

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

23 days ago - By: Cellectis Inc.

Cellectis publie un article dans Nature Communications sur un procédé d’édition génomique non viral efficace pour l’insertion génique dans les cellules souches hématopoïétiques

23 days ago - By: Cellectis Inc.

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

a month ago - By: Cellectis Inc.

Cellectis publie ses résultats financiers du troisième trimestre 2025 et une mise à jour de ses activités

a month ago - By: Cellectis Inc.

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Cellectis Inc.

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

a month ago - By: Cellectis Inc.

Monthly information on share capital and company voting rights

a month ago - By: Cellectis Inc.

Cellectis présentera de nouvelles avancées sur éti-cel lors du congrès annuel de l’ASH 2025

a month ago - By: Cellectis Inc.

Cellectis to Present a Development Update for eti-cel at ASH 2025

a month ago - By: Cellectis Inc.

Cellectis to Present a Development Update for eti-cel at ASH 2025

a month ago - By: Cellectis Inc.

Cellectis publiera ses résultats financiers du troisième trimestre le 7 novembre 2025

a month ago - By: Cellectis Inc.

Cellectis to Report Third Quarter Financial Results on November 7, 2025

a month ago - By: Cellectis Inc.

Cellectis to Report Third Quarter Financial Results on November 7, 2025

2 months ago - By: Cellectis Inc.

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

2 months ago - By: Cellectis Inc.

Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire

2 months ago - By: Cellectis Inc.

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

2 months ago - By: Cellectis Inc.

Cellectis organise aujourd’hui son R&D Day pour présenter les avancées de son portefeuille et ses perspectives à long terme

2 months ago - By: Cellectis Inc.

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

2 months ago - By: Cellectis Inc.

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

2 months ago - By: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

2 months ago - By: Cellectis Inc.

Monthly information on share capital and company voting rights

2 months ago - By: Cellectis Inc.

Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT

2 months ago - By: Cellectis Inc.

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

2 months ago - By: Cellectis Inc.

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress